Evaluation of Adiponectin as a Metabolic Risk Indicator in the Panamanian Population

Adiponectin, an adipokine secreted by adipocytes with anti-inflammatory and insulin-sensitizing properties, circulates in several isoforms, of which total and high-molecular-weight (HMW) adiponectin are the most physiologically relevant. While adiponectin has been inversely associated with obesity and metabolic syndrome (MetS), evidence from Latin American populations remains scarce. To explore its role in this context, we conducted a case–control study in 310 Panamanian adults, including 77 individuals with MetS and 233 controls, diagnosed according to the Latin American Diabetes Association (ALAD) criteria. Serum adiponectin, lipid profile, glucose, HbA1c, and body composition were evaluated, with adiponectin quantified by chemiluminescent immunoassay (CLIA). Correlations with metabolic parameters were analyzed using GraphPad Prism 10.5. Participants with MetS exhibited significantly lower adiponectin concentrations compared with controls (7.75 ± 2.58 µg/mL vs. 9.53 ± 3.31 µg/mL, p = 0.0030). Adiponectin levels were significantly lower in males than in females (p = 0.0083) and showed inverse correlations with visceral fat (r = −0.26, p < 0.001), triglycerides (r = −0.25, p = 0.0062), insulin (r = −0.31, p < 0.0001), and HbA1c (r = −0.11, p = 0.046). Conversely, a positive association was observed with HDL cholesterol (r = 0.37, p < 0.0001). Individuals with HbA1c ≥ 6.5% or insulin ≥ 15 µU/mL exhibited markedly reduced adiponectin concentrations (p = 0.0006 and p < 0.0001, respectively). The ROC analysis yielded an AUC of 0.69, indicating a moderate discriminatory ability of adiponectin for identifying MetS in this population. These findings confirm that adiponectin is inversely associated with several metabolic risk factors, supporting its potential utility as a biomarker for early detection and risk stratification of metabolic syndrome in the Panamanian population.